THAILAND

Patients to gain cancer drug access

News, Post Reporters, Published on 04/12/2025

» The government has approved new reimbursement rules enabling patients with advanced non-small cell lung cancer (NSCLC) to use targeted therapies, Erlotinib or Gefitinib, as first-line treatment, effective for medical expenses incurred from Dec 1 onwards.